DM Clinical Research Celebrates 20 Years of Expanding Clinical Trial Access

DM Clinical Research is celebrating its 20th anniversary, marking two decades of expanding access to clinical trials and helping accelerate the development of innovative therapies for patients across the United States. Founded in 2006 with a vision to make clinical research more accessible and patient-centered, DM Clinical has grown into one of the nation's leading integrated clinical research networks. Over the past 20 years, the organization expanded its national footprint, therapeutic expertise, and research capabilities while remaining focused on accelerating access to innovative therapies.

"Reaching 20 years is incredibly meaningful to me. When I think about DM Clinical Research, I think first about the people, the employees who have poured their talent and heart into this organization, and the patients who have trusted us to be part of their healthcare journey," said Mohammad Millwala, Founder and CEO of DM Clinical Research. "We've experienced so much growth and change over the past two decades, but what has never changed is our commitment to our patients and to doing meaningful work that makes a difference. I'm incredibly proud of what we've built together, and I'm even more excited about what we can accomplish in the next 20 years."

Today, DM Clinical Research operates a growing network of more than 35 research sites, providing access to a patient population of 1.97 million individuals across 32 therapeutic areas. Over the past 20 years, DM Clinical Research has enrolled more than 35,000 patients in clinical trials, helping advance the development of safe, life-changing therapies for patients and communities around the world. This scale and reach have positioned the company as a key player in the clinical research industry, enabling sponsors and CRO partners to conduct high-quality trials with strong enrollment performance and diverse patient access.

The company's impact extends beyond numbers. DM Clinical Research partners with leading pharmaceutical, biotechnology, healthcare organizations, and contract research organizations to conduct clinical trials while delivering operational excellence. As part of its mission to expand access to clinical research, DM Clinical Research continues to grow its presence in underserved communities, helping ensure more patients have the opportunity to participate in life-changing clinical trials. Through its integrated operating model, DM Clinical combines local physician relationships and patient access with centralized infrastructure designed to deliver quality, speed, and consistent execution for sponsors and CRO partners.

This commitment to excellence and patient impact has been recognized through industry honors, including the [SPRIA Award for vaccine enrollment](https://example.com/sria-award), the [Excellence in Patient Centricity Award](https://example.com/excellence-award), [ViE's Best Clinical Trial Network Award](https://example.com/vie-award), and the [SCRS Site Spark Award](https://example.com/scrs-award). In 2025, DM Clinical Research CEO Mohammad Millwala was also honored with the [SCRS Christine K. Pierre Site Impact Award](https://example.com/christine-pierre-award), recognizing his leadership and contributions to advancing clinical research.

The company's 20th anniversary theme, "Champions of Clinical Research: 20 Years of Impact," reflects the teamwork, innovation, and dedication that have fueled its growth over the past two decades. Guided by its core values, Think Forward, Find a Way, Create Impact, Own It, and Win Together, DM Clinical continues to invest in its people, expand access to research, and help bring new therapies to patients faster.

"As we celebrate this milestone, we remain focused on what's next," added Millwala. "The next chapter for DM Clinical is about expanding access to research, embracing new technologies, and ensuring more patients have the opportunity to participate in clinical trials that can change lives." As DM Clinical enters its third decade, the company plans continued expansion into new communities, broader therapeutic expertise, and increased investment in innovative technologies that improve patient access to clinical research. This growth trajectory underscores the company's role in shaping the future of clinical research in Texas and beyond, making a tangible difference in the lives of patients and the advancement of medical science.